NasdaqCM - Nasdaq Real Time Price USD

Silo Pharma, Inc. (SILO)

0.4750
+0.0200
+(4.40%)
As of 11:49:57 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
72.1020
72.1020
72.1020
72.1020
71.2640
Cost of Revenue
5.8380
5.8380
5.8380
5.8380
5.0040
Gross Profit
66.2640
66.2640
66.2640
66.2640
66.2600
Operating Expense
4,986.5660
4,771.9580
3,921.8560
3,713.9200
2,959.1030
Operating Income
-4,920.3020
-4,705.6940
-3,855.5920
-3,647.6560
-2,892.8430
Net Non Operating Interest Income Expense
301.5360
328.0810
393.6610
70.4380
-1.8260
Other Income Expense
-3.8840
-15.2670
-169.1520
-330.1700
7,076.6530
Pretax Income
-4,622.6500
-4,392.8800
-3,631.0830
-3,907.3880
4,181.9840
Tax Provision
0
0
0
0
24.8760
Net Income Common Stockholders
-4,622.6500
-4,392.8800
-3,700.6830
-3,908.5510
2,499.7440
Diluted NI Available to Com Stockholders
-4,622.6500
-4,392.8800
-3,700.6830
-3,908.5510
2,499.7440
Basic EPS
-1.14
--
-1.20
-1.71
1.32
Diluted EPS
-1.14
--
-1.20
-1.71
1.30
Basic Average Shares
4,084.7700
--
3,079.8740
2,284.2400
1,897.3150
Diluted Average Shares
4,084.7700
--
3,079.8740
2,284.2400
1,918.4440
Total Operating Income as Reported
-4,920.3020
-4,705.6940
-3,855.5920
-3,627.6560
-2,744.3430
Total Expenses
4,992.4040
4,777.7960
3,927.6940
3,719.7580
2,964.1070
Net Income from Continuing & Discontinued Operation
-4,622.6500
-4,392.8800
-3,700.6830
-3,908.5510
3,903.7410
Normalized Income
-4,618.7660
-4,377.6130
-3,461.9310
-3,577.2180
-2,877.4504
Interest Income
306.8160
333.1650
398.5300
72.6370
1.2100
Interest Expense
5.2800
5.0840
4.8690
2.1990
3.0360
Net Interest Income
301.5360
328.0810
393.6610
70.4380
-1.8260
EBIT
-4,617.3700
-4,387.7960
-3,626.2140
-3,905.1890
4,185.0200
EBITDA
-4,608.0930
-4,381.6110
-3,626.2140
-3,905.1890
4,185.0200
Reconciled Cost of Revenue
5.8380
5.8380
5.8380
5.8380
5.0040
Reconciled Depreciation
9.2770
6.1850
0
--
--
Net Income from Continuing Operation Net Minority Interest
-4,622.6500
-4,392.8800
-3,631.0830
-3,907.3880
4,157.1080
Total Unusual Items Excluding Goodwill
-3.8840
-15.2670
-169.1520
-330.1700
7,076.6530
Total Unusual Items
-3.8840
-15.2670
-169.1520
-330.1700
7,076.6530
Normalized EBITDA
-4,604.2090
-4,366.3440
-3,457.0620
-3,575.0190
-2,891.6330
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
42.0946
12/31/2021 - 1/8/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

INTS Intensity Therapeutics, Inc.
0.5244
-11.27%
 
ERNA Ernexa Therapeutics Inc.
0.1800
-17.81%
 
TNFA TNF Pharmaceuticals, Inc.
0.1657
-3.10%
 
AEON AEON Biopharma, Inc.
0.5633
+2.37%
 
ZVSA ZyVersa Therapeutics, Inc.
0.6600
+0.57%
 
BDRX Biodexa Pharmaceuticals Plc
1.1600
+0.87%
 
ABP Abpro Corporation
0.2139
-2.73%
 
PCSA Processa Pharmaceuticals, Inc.
0.2996
+0.54%
 
ENVB Enveric Biosciences, Inc.
1.2912
+4.98%
 
REVB Revelation Biosciences, Inc.
1.1306
+37.38%